CAPRICOR THERAPEUTICS, INC.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $CAPR in the last 30 days.
See all $CAPR insider activity →Oppenheimer reiterated an Outperform rating and $54 price target for Capricor Therapeutics (CAPR) after a webinar on FDA data, citing robust HOPE-3 trial results. The stock is down 74% in six months. Other analysts also upgraded CAPR, with targets up to $25, anticipating regulatory milestones.
Capricor Therapeutics (CAPR) shares rose 5% after presenting additional heart data for Deramiocel ahead of an FDA decision on November 22. The company submitted 24-month clinical data analyses, focusing on preserving upper-limb function. The FDA initially rejected the therapy in July 2025, citing insufficient evidence, and an advisory committee recently voted 9-3 against its effectiveness for cardiomyopathy. CAPR stock is down 72% year-to-date.
Capricor presented two-year data on deramiocel, showing a 1.56-point difference in upper-limb decline for the delayed-start group. Patients treated for two years had a 3.4-point decline in PUL 2.0. Cardiac MRI data showed a 2.8% treatment effect on LVEF. The company plans to explore regulatory pathways outside the U.S. and monitor safety in combination therapies.
Over the past 7 days, AlphAI's AI scored 8 news stories mentioning CAPR (CAPRICOR THERAPEUTICS, INC.). Coverage has skewed bullish: 7 bullish, 0 neutral, and 1 bearish.
Recent CAPR coverage spans financial news, market movers and regulation.
Analyst rating and high price target suggest upside potential for CAPR.
The new FDA timeline and data could lift the stock as investors price in a higher chance of approval.
Positive trial outcomes suggest a potential regulatory approval, likely driving share price upside.
Positive trial data may lift CAPR as investors reassess the therapy's commercial potential.
Positive trial data and pending BLA decision could drive share upside if FDA approval is granted.
AlphAI scores every news story that mentions CAPR with an AI model for sentiment and relevance, and aggregates insider trades from CAPRICOR THERAPEUTICS, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Oppenheimer reiterated an Outperform rating and $54 price target for Capricor Therapeutics (CAPR) after a webinar on FDA data, citing robust HOPE-3 trial results. The stock is down 74% in six months. Other analysts also upgraded CAPR, with targets up to $25, anticipating regulatory milestones.
2 min readCapricor Therapeutics (CAPR) shares rose 5% after presenting additional heart data for Deramiocel ahead of an FDA decision on November 22. The company submitted 24-month clinical data analyses, focusing on preserving upper-limb function. The FDA initially rejected the therapy in July 2025, citing insufficient evidence, and an advisory committee recently voted 9-3 against its effectiveness for cardiomyopathy. CAPR stock is down 72% year-to-date.
1 min readCapricor presented two-year data on deramiocel, showing a 1.56-point difference in upper-limb decline for the delayed-start group. Patients treated for two years had a 3.4-point decline in PUL 2.0. Cardiac MRI data showed a 2.8% treatment effect on LVEF. The company plans to explore regulatory pathways outside the U.S. and monitor safety in combination therapies.
2 min readCapricor Therapeutics (CAPR) presented 24-month data for deramiocel, a Duchenne muscular dystrophy treatment, at the World Muscle Society Congress. Patients switching from placebo to deramiocel showed a 76% reduction in upper limb decline. The FDA is reviewing the data, with a PDUFA target date of November 22, 2026. The study included 106 patients, with 98 entering the open-label extension.
2 min readCapricor Therapeutics reported that Deramiocel slowed upper limb decline by 76% in HOPE-3 OLE data. The company included this data in a BLA amendment, with an FDA target action date of Nov. 22, 2026.
1 min readCapricor Therapeutics (CAPR) presented positive 24-month data from its HOPE-3 open-label extension study for Deramiocel, showing a 76% reduction in upper limb decline for DMD patients who switched from placebo to treatment. Both treatment groups showed slower decline than natural history predicts. The data is included in Deramiocel's BLA major amendment, with a PDUFA target action date of November 22, 2026. A webinar is scheduled for October 7, 2026, to discuss the results.
2 min readCapricor Therapeutics (CAPR) shares rose 10.5% after 24-month data for its Duchenne muscular dystrophy therapy, deramiocel, was presented at a medical conference. The FDA is reviewing the data, with a decision expected by Nov. 22. Analyst B. Riley upgraded CAPR to 'Buy' with a $21 target, citing favorable data and FDA prospects. Retail sentiment has also turned bullish.
2 min readCapricor Therapeutics (CAPR) stock rose 13.54% to $9.73 in pre-market trading as its HOPE-3 poster on Deramiocel was presented at the World Muscle Society congress. The poster covers 24-month data, including a delayed-start analysis and natural-history comparison. Capricor previously submitted these analyses to the FDA as part of a major amendment to its BLA, pushing the PDUFA date to Nov. 22, 2026.
1 min readCapricor Therapeutics (CAPR) stock rose 13.28% after B. Riley and Piper Sandler upgraded it, setting price targets of $21 and $25 respectively, ahead of an FDA decision on its lead therapy, deramiocel, on November 22, 2026. The company reported a net loss of $40.7M and cash burn of $31M, but holds significant cash and minimal debt. Analysts' average price target is $31.78.
3 min readCapricor Therapeutics (CAPR) shares rose 17% after positive clinical data. Iovance Biotherapeutics (IOVA) gained 31% on raised revenue outlook. DraftKings (DKNG) fell 7% amid competitor funding news. Trade Desk (TTD) declined on revenue growth concerns. Dow is down for Q3, while S&P 500 and Nasdaq are up. PCE data release expected to impact markets.
2 min read
